Title |
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial
|
---|---|
Published in |
Trials, September 2014
|
DOI | 10.1186/1745-6215-15-367 |
Pubmed ID | |
Authors |
Samal Gunatilake, Fraser JH Brims, Carole Fogg, Iain Lawrie, Nick Maskell, Karen Forbes, Najib Rahman, Steve Morris, Reuben Ogollah, Stephen Gerry, Mick Peake, Liz Darlison, Anoop J Chauhan |
Abstract |
Malignant pleural mesothelioma is an incurable cancer caused by exposure to asbestos. The United Kingdom has the highest death rate from mesothelioma in the world and this figure is increasing. Median survival is 8 to 12 months, and most patients have symptoms at diagnosis. The fittest patients may be offered chemotherapy with palliative intent. For patients not fit for systemic anticancer treatment, best supportive care remains the mainstay of management. A study from the United States examining advanced lung cancer showed that early specialist palliative care input improved patient health related quality of life and depression symptoms 12 weeks after diagnosis. While mesothelioma and advanced lung cancer share many symptoms and have a poor prognosis, oncology and palliative care services in the United Kingdom, and many other countries, vary considerably compared to the United States. The aim of this trial is to assess whether regular early symptom control treatment provided by palliative care specialists can improve health related quality of life in patients newly diagnosed with mesothelioma. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
Unknown | 134 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 22 | 16% |
Researcher | 17 | 13% |
Student > Ph. D. Student | 12 | 9% |
Student > Bachelor | 12 | 9% |
Student > Postgraduate | 7 | 5% |
Other | 21 | 16% |
Unknown | 44 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 21% |
Nursing and Health Professions | 21 | 16% |
Psychology | 8 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
Social Sciences | 4 | 3% |
Other | 17 | 13% |
Unknown | 51 | 38% |